

# Jonathan R Whitfield

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4753633/publications.pdf>

Version: 2024-02-01

36  
papers

4,375  
citations

361413  
20  
h-index

501196  
28  
g-index

36  
all docs

36  
docs citations

36  
times ranked

5838  
citing authors

#	ARTICLE	IF	CITATIONS
1	A c-jun dominant negative mutant protects sympathetic neurons against programmed cell death. <i>Neuron</i> , 1995, 14, 927-939.	8.1	792
2	Modelling Myc inhibition as a cancer therapy. <i>Nature</i> , 2008, 455, 679-683.	27.8	706
3	Dominant-Negative c-Jun Promotes Neuronal Survival by Reducing BIM Expression and Inhibiting Mitochondrial Cytochrome c Release. <i>Neuron</i> , 2001, 29, 629-643.	8.1	528
4	Role of the Jun Kinase Pathway in the Regulation of c-Jun Expression and Apoptosis in Sympathetic Neurons. <i>Journal of Neuroscience</i> , 1998, 18, 1713-1724.	3.6	276
5	Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice. <i>Genes and Development</i> , 2013, 27, 504-513.	5.9	250
6	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	2.8	239
7	Strategies to Inhibit Myc and Their Clinical Applicability. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 10.	3.7	230
8	c-Jun and the transcriptional control of neuronal apoptosis. <i>Biochemical Pharmacology</i> , 2000, 60, 1015-1021.	4.4	218
9	Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	150
10	Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis. <i>Nature Communications</i> , 2014, 5, 4632.	12.8	144
11	Assembly of GABAAR Receptors Composed of $\alpha 1$ and $\alpha 2$ Subunits in Both Cultured Neurons and Fibroblasts. <i>Journal of Neuroscience</i> , 1997, 17, 6587-6596.	3.6	117
12	Transforming Growth Factor $\beta 2$ (TGF $\beta 2$ ) Mediates Schwann Cell Death <i>In Vitro</i> and <i>In Vivo</i> : Examination of c-Jun Activation, Interactions with Survival Signals, and the Relationship of TGF $\beta 2$ -Mediated Death to Schwann Cell Differentiation. <i>Journal of Neuroscience</i> , 2001, 21, 8572-8585.	3.6	104
13	The effect of environmental chemicals on the tumor microenvironment. <i>Carcinogenesis</i> , 2015, 36, S160-S183.	2.8	97
14	Ibrutinib Exerts Potent Antifibrotic and Antitumor Activities in Mouse Models of Pancreatic Adenocarcinoma. <i>Cancer Research</i> , 2015, 75, 1675-1681.	0.9	95
15	Direct inhibition of c-Jun N-terminal kinase in sympathetic neurones prevents c-Jun promoter activation and NGF withdrawal-induced death. <i>Journal of Neurochemistry</i> , 2001, 76, 1439-1454.	3.9	94
16	Tumor microenvironment: becoming sick of Myc. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 931-934.	5.4	63
17	Specific Requirement for Bax, Not Bak, in Myc-induced Apoptosis and Tumor Suppression <i>In Vivo</i> . <i>Journal of Biological Chemistry</i> , 2006, 281, 10890-10895.	3.4	54
18	The long journey to bring a Myc inhibitor to the clinic. <i>Journal of Cell Biology</i> , 2021, 220, .	5.2	51

#	ARTICLE	IF	CITATIONS
19	The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2005, 15, 4666-4670.	2.2	49
20	Tamoxifen Administration to Mice. <i>Cold Spring Harbor Protocols</i> , 2015, 2015, pdb.prot077966.	0.3	27
21	Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death. <i>Cell Death and Disease</i> , 2013, 4, e468-e468.	6.3	19
22	c-Jun and Bax: regulators of programmed cell death in developing neurons. <i>Biochemical Society Transactions</i> , 1999, 27, 790-797.	3.4	13
23	High-throughput methods to detect dimerization of Bcl-2 family proteins. <i>Analytical Biochemistry</i> , 2003, 322, 170-178.	2.4	13
24	The Estrogen Receptor Fusion System in Mouse Models: A Reversible Switch. <i>Cold Spring Harbor Protocols</i> , 2015, 2015, pdb.top069815.	0.3	12
25	BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC. <i>Oncotarget</i> , 2018, 9, 18734-18746.	1.8	12
26	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. <i>Cancer Research Communications</i> , 2022, 2, 110-130.	1.7	10
27	Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma. <i>Blood Advances</i> , 2021, 5, 5239-5257.	5.2	7
28	The Wnt signaling receptor Fzd9 is essential for Myc-driven tumorigenesis in pancreatic islets. <i>Life Science Alliance</i> , 2021, 4, e201900490.	2.8	4
29	Immunocytochemical Techniques for Studying Apoptosis in Primary Sympathetic Neurons. , 2004, 282, 169-178.		1
30	Editorial overview: Peptides in cancer. <i>Current Opinion in Pharmacology</i> , 2019, 47, iii-v.	3.5	0
31	An "Omomyc" Toolbox to Work with MYC. <i>Methods in Molecular Biology</i> , 2021, 2318, 1-11.	0.9	0
32	Abstract 4956: Pharmacological inhibition of Bruton's Tyrosine Kinase (BTK) as a therapy for insulinoma and pancreatic ductal adenocarcinoma. , 2013, , .		0
33	Abstract 2645: Preclinical validation of Myc inhibition by a new generation of Omomyc-based inhibitors. , 2015, , .		0
34	Abstract B23: Pushing Myc inhibition towards the clinic by direct delivery of cell-penetrating peptides. , 2015, , .		0
35	Abstract PR10: Preclinical validation of Myc inhibition by a new generation of Omomyc-based cell penetrating peptides. , 2015, , .		0
36	Abstract 2167: Preclinical validation of an Omomyc cell-penetrating peptide as a viable anti-Myc therapy. , 2017, , .		0